Alzheimer's Association Supports First Human Trials of NTRX-07

NeuroTherapia has received funding from the Alzheimer's Association to support the first human trials of NTRX-07, a novel new therapy targeted towards inflammation in the brain and nervous system.

The trial, set to begin in October, 2019, will study the pharmacology and safety of NTRX-07 in normal volunteers. The company plans to follow this study with a safety study in patients given NTRX-07 for up to one month.

NTRX-07 blocks neuro-inflammation, which has been identified as a cause of injury to the brain in Alzheimer's disease and other neurodegenerative diseases. Neuro-inflammation also plays an important role in the development of chronic neuropathic pain which may occur after injury or treatment with some chemotherapy agents.